Skip to main content

Advertisement

Table 1 Combined results of internal and external evaluations of the study

From: Piloting the role of a pharmacist in a community palliative care multidisciplinary team: an Australian experience

Program Levels Indicators Results, including phase of the study and evaluation strategy in which this was demonstrated
End results What long term changes occurred as a result of the project? • Improved knowledge of how/where to access information/medications/management by the team (Phases 1 and 2, online survey; Phase 3, focus groups)
   • Increased knowledge of palliative care medications and their use (Phases 1 and 2, online survey; Phase 3, focus groups)
   • Development of PILs - available on website of palliative care service (includes translations and MP3 files) (Phase 3)
   • Care pathway developed (Phase 1)
   • MRST developed (Phase 1)
   • Toolkit for use by other palliative care services (Phase 3)
Changes in practice and behaviour How did practice change as a result of project participation? • Acceptance of the role of a pharmacist within a team (Phases 1 and 2, online survey; Phase 3, focus groups)
   • Use of medication sheets in nursing folder for chemotherapy and other medications (Phases 2 and 3)
   • Documentation and process of obtaining emergency medications - reviewed as part of audit (Phases 2 and 3)
Changes in knowledge, attitudes, skills and aspirations (KASA) How did participants' knowledge, attitudes, skills and aspirations change as a result of project participation? • Increase in knowledge and skills of team with respect to medications and their management, and on complexity of medication regimens (Phases 1 and 2, online survey; Phase 3, focus groups)
Reactions How did participants and clients react to the project activities? • Project Pharmacist accepted as an allied health professional within the team (Phases 1 and 2, online survey; Phase 3, focus groups)
   • Team very positive (Phases 1 and 2, online survey; Phase 3, focus groups)
   • Patients/carers accepting of the Project Pharmacist as part of the team (Phase 2)
Participants Who participated and how many? • Project Team, Steering Committee, External Evaluator, Team members, staff working at the palliative care service (all involved in consultation and communication strategies)
   • 380 patients were screened using the MRST (Phases 2 and 3)
   • 52 home visits to patients for medication review (Phases 2 and 3)
Activities In what activities did the participants engage through the project? • In-services to team (Phase 2)
   • Education and information sessions for SMRPCC members and health professionals working within this consortium and at another consortium (Phase 2)
   • Medication screenings using the MRST and medication reviews in patients' homes (Phase 2)
   • Conferences and seminars (Phases 2 and 3)
   • Consultation with key stakeholders (all Phases)
   • Newsletter articles (all Phases)
Inputs Which personnel and other resources were used during the project? • Project Team/External Evaluator/Steering Committee (all Phases)
   • Members of the team (all Phases)
   • Staff working at the palliative care service (all Phases)
   • Clinical supervision and support (Phase 2)
   • Volunteers - assistance with reviewing and critique of PILs (morphine) (Phase 2)
   • Liaison with outreach pharmacists, clinical trial pharmacists, key stakeholders (all Phases).